公开(公告)号：US20130095085A1

公开(公告)日：2013-04-18

申请号：US13704424

申请日：2011-06-13

申请人： Taito Nishino ,  Atsushi Iwama

发明人： Taito Nishino ,  Atsushi Iwama

IPC分类号： C12N5/0789

CPC分类号： C12N5/0647 ,  A61K31/122 ,  A61K31/352 ,  C12N2500/62 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/26 ,  C12N2501/72 ,  C12N2501/727 ,  C12N2501/999

摘要： An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided.A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R1 to R6 are as defined in the description).

摘要翻译： 提供了用作造血干细胞和/或造血祖细胞的扩增剂，其用作各种造血疾病的治疗，并且可用于提高基因转移到造血干细胞中用于基因治疗的效率。 一种产生造血干细胞和/或造血祖细胞的方法，其包括通过在下列通式（I）表示的化合物存在下体外培养造血干细胞来扩大造血干细胞，其中所述化合物的互变异构体或药学上可接受的盐 化合物或其溶剂合物（其中R1至R6如说明书中所定义）。

公开(公告)号：US20120128640A1

公开(公告)日：2012-05-24

申请号：US13376280

申请日：2010-06-04

申请人： Taito Nishino ,  Shunsuke Iwamoto ,  Katsuaki Miyaji

发明人： Taito Nishino ,  Shunsuke Iwamoto ,  Katsuaki Miyaji

IPC分类号： A61K35/28 ,  C12N15/85 ,  C12N5/077 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D333/32 ,  A61K35/00 ,  A61P7/00 ,  A61P37/06 ,  A61P37/04 ,  A61P9/10 ,  A61P25/00 ,  A61P19/00 ,  C12N5/02

CPC分类号： C07D333/32 ,  C07D333/38 ,  C07D409/12 ,  C07D409/14 ,  C12N5/0647 ,  C12N2501/999

摘要： An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided.An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells containing a compound represented by the formula (I) (wherein X, Y, Z, Ar1, R1, R2, R3, R4, R5, R6 and R7 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof, which can expand hematopoietic stem cells and/or hematopoietic progenitor cells.

摘要翻译： 提供了用于造血干细胞和/或造血祖细胞的扩增剂，其用于改善用于治疗各种疾病的基因治疗的造血干细胞的基因转移效率。 含有由式（I）表示的化合物的造血干细胞和/或造血祖细胞的扩增剂（其中X，Y，Z，Ar 1，R 1，R 2，R 3，R 4，R 5，R 6和R 7如 描述），可以扩大造血干细胞和/或造血祖细胞的化合物或其溶剂合物的互变异构体，前药或药学上可接受的盐。

公开(公告)号：US20100310536A1

公开(公告)日：2010-12-09

申请号：US12746497

申请日：2008-12-05

申请人： Takanori Nakamura ,  Atsushi Miyamura ,  Taito Nishino ,  Norihisa Ishiwata ,  Katsuaki Miyaji

发明人： Takanori Nakamura ,  Atsushi Miyamura ,  Taito Nishino ,  Norihisa Ishiwata ,  Katsuaki Miyaji

IPC分类号： A61K35/12 ,  C12N5/078 ,  A61P35/00 ,  A61P7/00

CPC分类号： C12N5/0647 ,  A61K2035/124 ,  C07D231/12 ,  C07D333/22 ,  C07D409/12 ,  C07D409/14 ,  C07D417/14 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/999

摘要： An object of the present invention is to expand CD34+ cells ex vivo efficiently in a short term using a biologically safe and inexpensively obtainable low molecular weight compound. A still another object of the present invention is to provide an expansion agent for CD34+ cells useful for treatment of various hematopoietic disorders caused by dysfunctional hematopoietic stem cells and/or hematopoietic progenitor cells.A method for expanding CD34+ cells, which comprises culturing CD34+ cells ex vivo in the presence of a compound represented by the formula (I) (wherein A, B, L1, L2, L3, L4, R1, R2, R3, X and Y are defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.

摘要翻译： 本发明的目的是使用生物安全且廉价的低分子量化合物在短期内有效地扩增CD34 +细胞。 本发明的另一个目的是提供用于治疗由功能异常的造血干细胞和/或造血祖细胞引起的各种造血障碍的CD34 +细胞的扩张剂。 一种用于扩增CD34 +细胞的方法，其包括在式（I）表示的化合物（其中A，B，L1，L2，L3，L4，R1，R2，R3，X和Y）存在下离体培养CD34 +细胞 在描述中定义），化合物的互变异构体或药学上可接受的盐或其溶剂合物。

公开(公告)号：US09187728B2

公开(公告)日：2015-11-17

申请号：US13704424

申请日：2011-06-13

申请人： Taito Nishino ,  Atsushi Iwama

发明人： Taito Nishino ,  Atsushi Iwama

IPC分类号： A61K38/00 ,  C12N5/00 ,  C12N5/0789 ,  A61K31/122 ,  A61K31/352

CPC分类号： C12N5/0647 ,  A61K31/122 ,  A61K31/352 ,  C12N2500/62 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/26 ,  C12N2501/72 ,  C12N2501/727 ,  C12N2501/999

摘要： An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided.A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R1 to R6 are as defined in the description).

摘要翻译： 提供了用作造血干细胞和/或造血祖细胞的扩增剂，其用作各种造血疾病的治疗，并且可用于提高基因转移到造血干细胞中用于基因治疗的效率。 一种产生造血干细胞和/或造血祖细胞的方法，其包括通过在下列通式（I）表示的化合物存在下体外培养造血干细胞来扩大造血干细胞，其中所述化合物的互变异构体或药学上可接受的盐 化合物或其溶剂合物（其中R1至R6如说明书中所定义）。

公开(公告)号：US09115341B2

公开(公告)日：2015-08-25

申请号：US12746507

申请日：2008-12-05

申请人： Takanori Nakamura ,  Atsushi Miyamura ,  Taito Nishino ,  Norihisa Ishiwata ,  Katsuaki Miyaji

发明人： Takanori Nakamura ,  Atsushi Miyamura ,  Taito Nishino ,  Norihisa Ishiwata ,  Katsuaki Miyaji

IPC分类号： C12N5/00 ,  C12N5/0789 ,  C07D333/02 ,  C07D207/00 ,  A61K35/12

CPC分类号： C12N5/0647 ,  A61K35/12 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/999

摘要： An object of the present invention is to expand CD34+ cells ex vivo efficiently in a short term using a biologically safe and inexpensively obtainable low molecular weight compound. A still another object of the present invention is to provide an expansion agent for CD34+ cells useful for treatment of various hematopoietic disorders caused by dysfunctional hematopoietic stem cells and/or hematopoietic progenitor cells.A method for expanding CD34+ cells, which comprises culturing CD34+ cells ex vivo in the presence of a compound represented by the formula (I) (wherein A, B, L1, L2, L3, L4, R1, R2, R3, X and Y are defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.

摘要翻译： 本发明的目的是使用生物安全且廉价的低分子量化合物在短期内有效地扩增CD34 +细胞。 本发明的另一个目的是提供用于治疗由功能异常的造血干细胞和/或造血祖细胞引起的各种造血障碍的CD34 +细胞的扩张剂。 一种用于扩增CD34 +细胞的方法，其包括在式（I）表示的化合物（其中A，B，L1，L2，L3，L4，R1，R2，R3，X和Y）存在下离体培养CD34 +细胞 在描述中定义），化合物的互变异构体或药学上可接受的盐或其溶剂合物。

公开(公告)号：US20140057353A1

公开(公告)日：2014-02-27

申请号：US13990959

申请日：2011-12-01

申请人： Ayako Asai ,  Taito Nishino ,  Makiko Yui

发明人： Taito Nishino ,  Makiko Yui ,  Yasuyuki Asai

IPC分类号： C12N5/0789 ,  C07D231/22

CPC分类号： C12N5/0647 ,  A61K35/28 ,  C07D231/22 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/26 ,  C12N2501/999

摘要： An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided.A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R1 to R8 are as defined in the description).

摘要翻译： 提供了用作造血干细胞和/或造血祖细胞的扩增剂，其用作各种造血疾病的治疗，并且可用于提高基因转移到造血干细胞中用于基因治疗的效率。 一种产生造血干细胞和/或造血祖细胞的方法，其包括通过在下列通式（I）表示的化合物存在下体外培养造血干细胞来扩大造血干细胞，其中所述化合物的互变异构体或药学上可接受的盐 化合物或其溶剂化物（其中R1至R8如说明书中所定义）。

公开(公告)号：US20130253204A1

公开(公告)日：2013-09-26

申请号：US13991024

申请日：2011-12-01

申请人： Taito Nishino ,  Katsuaki Miyaji ,  Shunsuke Iwamoto ,  Takumi Mikashima ,  Koichiro Saruhashi ,  Yo Kishikawa

发明人： Taito Nishino ,  Katsuaki Miyaji ,  Shunsuke Iwamoto ,  Takumi Mikashima ,  Koichiro Saruhashi ,  Yo Kishikawa

IPC分类号： C07D231/20

CPC分类号： C07D231/20 ,  C07D401/06 ,  C07D403/06

摘要： Novel therapeutic agents for myeloma are provided.A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): wherein R1 is C1-C6 alkyl, C1-C6 alkyl substituted with R17, C1-C6 haloalkyl, phenyl, phenyl substituted with a R11's or the like, R2 is a hydrogen atom, C1-C6 alkyl, phenyl or phenyl optionally substituted with e R21's or the like, R3 is a hydrogen atom or the like, X is a single bond or —(CR6, R7)n—, each of R4 and R5 is independently C1-C6 alkyl or the like, R6 and R7 are hydrogen atoms or C1-C6 alkyl, R8 is phenyl, phenyl optionally substituted with k R81's or the like, a tautomer of the compound or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

摘要翻译： 提供了新型骨髓瘤治疗剂。 一种含有由式（1）表示的吡唑化合物的多发性骨髓瘤治疗剂：其中R1是C1-C6烷基，被R17取代的C1-C6烷基，C1-C6卤代烷基，苯基，被R11等取代的苯基， R 2是氢原子，C 1 -C 6烷基，苯基或任选被e R 21等取代的苯基，R 3是氢原子等，X是单键或 - （CR 6，R 7）n - ，每个R 4 并且R 5独立地为C 1 -C 6烷基等，R 6和R 7为氢原子或C 1 -C 6烷基，R 8为苯基，任选被k R 81等取代的苯基，化合物的互变异构体或其药学上可接受的盐或溶剂合物 作为活性成分。

公开(公告)号：US20050282730A1

公开(公告)日：2005-12-22

申请号：US10524666

申请日：2003-08-14

申请人： Katsuaki Miyaji ,  Norihisa Ishiwata ,  Takanori Nakamura ,  Taito Nishino ,  Hisao Kamiya ,  Masao Yamamoto

发明人： Katsuaki Miyaji ,  Norihisa Ishiwata ,  Takanori Nakamura ,  Taito Nishino ,  Hisao Kamiya ,  Masao Yamamoto

IPC分类号： A61K31/277 ,  A61K31/4402 ,  A61K31/4409 ,  A61K31/4453 ,  A61P7/00 ,  A61P7/04 ,  A61P7/06 ,  A61P9/08 ,  A61P9/10 ,  A61P43/00 ,  C07C255/37 ,  A61K38/00

CPC分类号： A61K31/4409 ,  A61K31/277 ,  A61K31/4402 ,  A61K31/4453 ,  C07C255/37

摘要： A preventive, therapeutic or improving agent for diseases against which activation of the thrombopoietin receptor is effective or a platelet increasing agent, which contains a thrombopoietin receptor activator represented by the formula (1): [wherein each of R1 and R3 is independently a hydrogen atom, SO3H, a C1-6 alkyl group, a C1-6 alkylcarbonyl group or a C6-18 arylcarbonyl group (the C1-6 alkyl group, the C1-6 alkylcarbonyl group and the C6-18 arylcarbonyl group may be optionally substituted with a halogen atom, a hydroxyl group, a C2-6 alkenyl group, a C1-6 alkoxy group, a C1-6 alkoxycarbonyl group, a C6-18 aryl group, a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-furanyl group, a 3-furanyl group, a 2-thienyl group, a 3-thienyl group or NR9R10) , and each of R2, R4 and Ra is independently a hydrogen atom, a hydroxyl group or a C1-6 alkoxy group].

摘要翻译： 含有血小板生成素受体活化剂的式（1）所示的预防，治疗或改善剂，其用于血小板生成素受体活化有效的疾病或血小板增加剂：[其中R 1〜 >和R 3独立地是氢原子，SO 3 H，C 1-6烷基，C 1〜 C 6烷基羰基或C 6-18芳基羰基（C 1-6烷基，C 1-6 - 烷基羰基和C 6-18芳基羰基可以任选地被卤素原子，羟基，C 2-6亚烯基，C 1 -C 6烷基， 1-6个烷氧基，C 1-6烷氧基羰基，C 6-18芳基，2-吡啶基，3-吡啶基 基团，4-吡啶基，2-呋喃基，3-呋喃基，2-噻吩基，3-噻吩基或NR9R10 ），并且R 2，R 4和R 9中的每一个 >独立地是氢原子，羟基或C 1-6烷氧基]。